Author details

Full Name

Scott L Carter

Affiliation

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35176131	CNGPLD: case-control copy-number analysis using Gaussian process latent difference.	Bioinformatics	2022
36040167	Tangent normalization for somatic copy-number inference in cancer genome analysis.	Bioinformatics	2022
35706413	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.	Cancer Immunol Res	2022
34642316	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.	Nat Commun	2021
33637765	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.	Nat Commun	2021
34824235	Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.	Nat Commun	2021
34369989	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.	JAMA network open	2021
35122016	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.	Nat Cancer	2021
34642329	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.	Nat Commun	2021
32555425	Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.	Nat Med	2020
32483359	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.	Nat Med	2020
32270710	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.	Future Oncol	2020
31253631	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.	Clin Cancer Res	2019
31173106	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.	Neuro Oncol	2019
31164371	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.	Clin Cancer Res	2019
30796030	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain Metastases.	Clin Cancer Res	2019
30723112	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	Blood Adv	2019
29608884	Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.	Gastroenterology	2018
30123936	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.	Acta Neuropathol	2018
29903880	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.	Cancer Discov	2018
28170043	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.	Neuro Oncol	2017
32913968	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.	JCO Precis Oncol	2017
28594900	Systematic genomic and translational efficiency studies of uveal melanoma.	PLoS One	2017
29259186	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.	Nat Commun	2017
27707790	Landscape of Genomic Alterations in Pituitary Adenomas.	Clin Cancer Res	2017
27852700	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.	Clin Cancer Res	2017
27797976	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.	Clin Cancer Res	2017
28228279	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.	Immunity	2017
27905446	Genomic evolution and chemoresistance in germ-cell tumours.	Nature	2016
28741536	Brain Metastasis: Clinical Implications of Branched Evolution.		2016
27348297	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.	Nat Genet	2016
27199251	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.	Nat Commun	2016
27167109	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.	Oncotarget	2016
26536169	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.	N Engl J Med	2016
26061751	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.	N Engl J Med	2015
25957691	Prospective derivation of a living organoid biobank of colorectal cancer patients.	Cell	2015
26014096	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.	Cancer Immunol Res	2015
26181029	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.	JAMA Oncol	2015
26466571	Mutations driving CLL and their evolution in progression and relapse.	Nature	2015
26410082	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer Discov	2015
26192918	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nat Genet	2015
24836576	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.	Nat Med	2014
25589003	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.	Acta Neuropathol Commun	2014
25295501	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	N Engl J Med	2014
25512523	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proc Natl Acad Sci U S A	2014
24265154	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.	Cancer Discov	2014
24265153	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer Discov	2014
24390348	Landscape of genomic alterations in cervical carcinomas.	Nature	2014
23979521	Clonal evolution in hematological malignancies and therapeutic implications.	Leukemia	2014
24434212	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.	Cancer Cell	2014